(A) SARS-CoV-2 pseudovirus was pre-treated with LMWH enoxaparin (250 IU/mL), or different neutralizing antibodies against SARS-CoV-2 (COVA1-18, COVA1-21 and COVA2-15) and a humanIgG1 isotype control at concentrations of 100 pg/mL, 500 pg/mL, 1 ng/mL, 5 ng/mL, 10 ng/mL and 50 ng/mL for 30 min at 37°C. Binding of pseudovirus to Syndecan 1 expressing cells in absence or presence of LMWH enoxaparin or antibodies was determined by ELISA. Data information: Data show the mean values and error bars are the SEM. Statistical analysis was performed using (A) ordinary one-way with Dunnett's multiple-comparison test. *P≤0.05, **P≤0.01 (n=3) 